Soru

Zorluk: OrtaCardiovascular System

An unaccompanied 72-year-old woman is triaged in the acute care unit after experiencing 48 hours of constant chest "fluttering" and progressive exertional breathlessness. She has a known medical history of severe chronic obstructive pulmonary disease (COPD), for which she uses a daily umeclidinium-vilanterol inhaler, and essential hypertension. Upon evaluation, her vital signs are:

- Temperature: 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F})
- Blood pressure: 124/82 mm Hg124/82\text{ mm Hg}
- Heart rate: 148/min148/\text{min} and irregularly irregular
- Respiratory rate: 22/min22/\text{min}
- Oxygen saturation: 95%95\% on room air

Physical examination reveals a completely irregular cardiac rhythm with absent murmurs, rubs, or gallops. Pulmonary auscultation reveals a prolonged expiratory phase globally, but no focal crackles, rhonchi, or active wheezing are appreciated. There is no jugular venous distension or peripheral edema.

Initial laboratory testing yields the following results:
- Leukocyte count: 7,200/mm37,200/\text{mm}^3
- Thyroid-stimulating hormone (TSH): 2.8 μU/mL2.8\text{ }\mu\text{U/mL} (Normal: 0.4−4.0 μU/mL0.4-4.0\text{ }\mu\text{U/mL})
- Free T4: 1.1 ng/dL1.1\text{ ng/dL} (Normal: 0.9−1.7 ng/dL0.9-1.7\text{ ng/dL})

Arterial blood gas (room air):
- pH: 7.487.48
- PaCO 2_2: 31 mm Hg31\text{ mm Hg}
- PaO 2_2: 76 mm Hg76\text{ mm Hg}

A 12-lead electrocardiogram demonstrates an irregularly irregular rhythm with narrow QRS complexes and an absence of discernible P waves.

Which of the following is the most appropriate initial pharmacologic intervention for this patient's current condition?

  1. Intravenous diltiazemCevap
  2. B
    Nebulized albuterol and oral prednisone
  3. C
    Intravenous azithromycin
  4. D
    Oral methimazole
  5. E
    Intravenous sodium bicarbonate

Cevap

Intravenous diltiazem
The patient is presenting with hemodynamically stable atrial fibrillation with rapid ventricular response (RVR). Her primary symptom of breathlessness is a direct consequence of reduced diastolic filling time due to the profound tachycardia. The most appropriate initial management is rate control. In a patient with a history of severe chronic obstructive pulmonary disease (COPD), non-dihydropyridine calcium channel blockers (such as diltiazem or verapamil) are preferred over beta-blockers. Non-selective beta-blockers carry a risk of precipitating bronchospasm by antagonizing beta-2 receptors in the lungs, which would exacerbate her underlying pulmonary disease. Therefore, intravenous diltiazem is the safest and most effective choice to achieve rate control in this clinical context.

Adım Adım Çözüm

1
Interpret the clinical presentation and electrocardiogram findings.
The patient is experiencing atrial fibrillation with rapid ventricular response (RVR).
The irregularly irregular pulse, absence of P waves, and heart rate of 148/min confirm the diagnosis of atrial fibrillation.
2
Determine the hemodynamic stability of the patient.
The patient is hemodynamically stable.
Her blood pressure is 124/82 mm Hg, and there is no evidence of cardiogenic shock, ischemic chest pain, or altered mental status, indicating that pharmacologic rate control is appropriate rather than synchronized cardioversion.
3
Select the optimal rate-controlling agent considering the patient's comorbidities.
Intravenous diltiazem is selected over beta-blockers.
The patient has a history of severe chronic obstructive pulmonary disease (COPD). Non-selective beta-blockers carry a risk of precipitating bronchospasm by antagonizing beta-2 receptors in the lungs. Therefore, non-dihydropyridine calcium channel blockers like diltiazem are the preferred agents.

Anahtar Kavram

In patients with hemodynamically stable atrial fibrillation and comorbid chronic obstructive pulmonary disease (COPD), non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil) are the preferred agents for acute rate control to avoid bronchospastic risks associated with beta-blockers.
Bu soruyu puanla